News
Date | Subject |
2018-05- | Taiwan FDA Approves Phase I Clinical Trial of NEGF (BB-101) for the |
Treatment of Diabetic Foot Ulcers. | |
2018-05-23 | Patent application of “A composition for wound healing and use thereof” |
was granted by European Patent Office. | |
2018-04-11 | Awarded grant funding of $15M NTD for “Phase I Clinical Study Program |
for Wound Therapy Protein Drug BB-101” from Department of Industrial | |
Technology of MOEA. | |
2015-11-24 | US FDA Approves Phase I Clinical Trial of NEGF (BB-101) for the |
Treatment of Diabetic Foot Ulcers. | |
From drug discovery to clinical trial, all the development works of BB-101 | |
Blue Blood. FDA’s approval for clinical trial is an important milestone not only for Blue | |
is executed by Blue Blood. FDA’s approval for clinical trial is an important | |
milestone not only for Blue Blood, but also for Taiwan Biotechnology | |
Industry. |
--------------------------------------------
2013-06-21 | Patent application of “A composition for wound healing and use thereof” |
was granted by Taiwan Intellectual Property Office. | |
2013-06-11 | Patent application of “Methods and compositions for bactericide, |
bacteriostatic and anti-inflammation” was granted by Japan Patent Office. | |
2013-05-28 | Patent application of “Methods and compositions for bactericide, |
bacteriostatic and anti-inflammation” was granted by Korean Intellectual | |
Property Office. | |
2013-05-20 | The ongoing NEGF protein preclinical study was successfully awarded the |
Industrial R&D Promotional Loans of 27M NTD from Industrial | |
Development Bureau, Ministry of Economic Affairs. | |
2013-03-05 | In collaboration with Charles River Laboratories, U.S.A, BlueBlood |
effectively conducted the 28-day repeat dose dermal toxicity study in | |
mini-pigs. | |
2013-02-05 | BlueBlood has partnered with Dow Pharmaceuticals Sciences (U.S.A) on |
GMP manufacturing of Phase I clinical supplies |
--------------------------------------------
2012-10-23 | Patent application of “Method for treating wounds using an EGF-like |
domain of Thrombomodulin” was granted by United States Patent and | |
Trademark Office. | |
2012-10-23 | Patent application of “Methods and compositions for treating ischemia” was |
granted by United States Patent and Trademark Office. | |
2012-09-17 | Awarded grant funding of $15M NTD for “Preclinical Study Program for |
Wound Therapy Protein Drug BB-101” from Department of Industrial | |
Technology of MOEA. | |
2012-07-16 | Engaged Associate Professor Chuan-Liang Kao as technical consultant in |
developing Neutralization assay and antibody screening diagnostic kit for | |
Cytomegalovirus. | |
2012-06-12 | Conducted a GLP-compliance study: “A 28-day Study of NEGF by |
Subcutaneous Injection in Rats with a 16-day Recovery Period” at Charles | |
River Laboratories Inc. | |
2012-06-11 | Patent application of “Methods and compositions for bactericide, |
bacteriostatic and anti-inflammation” was granted by Taiwan Intellectual | |
Property Office. | |
2012-04-01 | Patent application of “Methods and compositions for bactericide, |
bacteriostatic and anti-inflammation” was granted by European Patent | |
Office. |
-------------------------------------------
2011-11-30 | Patent application of “Methods and compositions for bactericide, |
bacteriostatic and anti-inflammation” was granted by Intellectual Property | |
Office of Singapore. | |
2011-11-16 | Attend pre-IND meeting with US FDA for topical recombinant NEGF |
(BB-101). | |
2011-09-06 | Patent application of “A composition for wound healing and use thereof” |
was granted by Japan Patent Office. | |
2011-05-10 | Patent application of “Dextromethorphan-Based Method for Treating Acne” |
was granted by United States Patent and Trademark Office. | |
2011-04-28 | Patent application of “A composition for wound healing and use thereof” |
was granted by Korean Intellectual Property Office. | |
2011-04-05 | Patent application of “Methods and compositions for bactericide, |
bacteriostatic and anti-inflammation” was granted by IP Australia. |